Agilon Health Inc. (AGL) Tops Q2 EPS by 96c ; Offers Guidance

Agilon Health Inc. (NYSE: AGL) reported Q2 EPS of $1.04, $0.96 better than the analyst estimate of $0.08. Revenue for the quarter came in at $1.49 billion versus the consensus estimate of $1.44 billion.

GUIDANCE:

Agilon Health Inc. sees Q3 2026 revenue of $1.44-1.47 billion, versus the consensus of $1.41 billion.

For earnings history and earnings-related data on Agilon Health Inc. (AGL) click here.

You May Also Be Interested In

• Fed's Hammack: Would Probably Need 'some Number' Of Rate Hikes
• BTIG Downgrades Sionna Therapeutics (SION) to Neutral, 'we were wrong on our PreciSION CF call'
• William Blair Downgrades Tenax Therapeutics (TENX) to Market Perform